Swiss HIV Cohort Study

Surial et al., TAF in HIV/HBV and renal dysfunction

Switching from TDF to TAF in HIV/HBV co-infected individuals with renal dysfunction – a prospective cohort study.   JAIDS Surial et al. aimed to evaluate the impact of replacing tenofovir disoproxil fumarate (TDF) with Tenofovir alafenamide (TAF) on estimated glomerular filtration rate (eGFR), urine protein-to-creatinine ratio, and alanine aminotransferase (ALT) levels in HIV/hepatitis B virus (HBV-) […]

Wan et al., HIV-1 reservoir size and decay under long-term suppressive ART

Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART.   Nature Communications The impact of the viral genome on the HIV-1 reservoir, i.e. its heritability, remains unknown. To address this question, Wan et al. aimed to investigate the heritability of the HIV-1 reservoir size and long-term decay using viral sequences and total […]

Kusejko et al., HIV long-term survivors among people who inject drugs

Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study: 1980 – 2018.    Antiviral Therapy Kusejko et al. aimed to study social, clinical and mental factors of long-term survivors (LTS) in the Swiss HIV Cohort Study, with a particular focus on […]

Carlisle et al., HCV genetic diversity and time since infection

HCV genetic diversity can be used to infer infection recency and time since infection.   Viruses HIV-1 genetic diversity can be used to infer time since infection and infection recency. Carlisle et al. aimed to investigate whether the same next-generation sequencing (NGS-) derived-diversity method can be applied to HCV, and to identify the region of […]

Sculier et al., DTG + FTC dual maintenance therapy in a nationwide study

Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL’HIV trial.   PLoS Medicine Sculier et al. aimed to assess the 48-week efficacy and safety of dolutegravir (DTG) + emtrictabine (FTC) dual maintenance therapy in virologically suppressed people living with HIV (PWHIV) […]

Kamal et al., Retention in care and cART adherence

An adherence-enhancing program increases retention in care in the Swiss HIV Cohort. Open Forum Infectious Diseases Kamal et al. tested a theory-based cognitive behavioral intervention to increase HIV treatment engagement and retention. The study hypothesis was that the interprofessional medication adherence program (IMAP) has the ability to increase retention in care by reinforcing pharmaceutical care […]

Engel et al., Telomere length and coronary artery disease in persons living with HIV

Telomere length, traditional risk factors, HIV-related factors and coronary artery disease events in Swiss persons living with HIV.   Clinical Infectious Disease Engel et al. aimed to evaluate any independent association of leukocyte telomere length (TL) with coronary artery disease (CAD) events in persons living with human immunodeficiency virus (PLWH), in the context of all […]

Braun et al., L’hépatite C peut être éliminée chez les HSH infectés par le VIH

L’hépatite C peut être éliminée chez les hommes infectés par le VIH qui ont des relations sexuelles avec d’autres hommes.    Clinical Infectious Disease Les hommes infectés par le VIH qui ont des relations sexuelles avec d’autres hommes peuvent être infectés par l’hépatite C lors de leurs rapports sexuels. Une combinaison de tests systématiques, de […]

Braun et al., L’epatite C può essere eliminata negli MSM con infezione HIV

L’epatite C può essere eliminata negli uomini che hanno rapporti con altri uomini con infezione HIV.   Clinical Infectious Disease Gli uomini con infezione HIV che hanno rapporti sessuali con altri uomini (MSM) possono infettarsi con il virus dell’epatite C (HCV) durante i rapporti sessuali. L’esecuzione sistematica di test per HCV, la prescrizione di medicamenti […]

Braun et al., Hepatitis C lässt sich bei HIV-positiven MSM eliminieren

Hepatitis C lässt sich bei HIV-positiven Männer, die Sex mit Männern haben, eliminieren.     Clinical Infectious Disease HIV-positive Männer, die Sex mit Männern haben, können sich über den sexuellen Weg mit Hepatitis C infizieren. Eine Kombination von systematischem Testen, hochwirksamen Hepatitis-C-Medikamenten und Verhaltensintervention kann die Viruserkrankung in dieser Risikogruppe eliminieren. Das zeigt eine vom Universitätsspital […]